ArticleTechnology in cancer research & treatment2019
Correlation Between Uptake of
Open access · goldAbstract read
In one paragraph
Article in Technology in cancer research & treatment, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers, 1 of them a synthesis that pooled it.
0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed, 1 pooled it
0.8field-weighted citation impact, top 26% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed, 1 synthesis or guideline pooled it, 9 citations in OpenAlex.
- Prognostic value ofEuropean radiology · 2021Pooled it
- Fulminant extramedullary relapse of multiple myeloma with rare cardiac, vascular, and multivisceral involvement: A case report.Therapeutic advances in hematology · 2026Article
- A rare case of CD38-negative abdominal multiple extramedullary plasmacytoma and literature review.Leukemia research reports · 2025Article
- The Ki-67 Proliferation Index-Related Nomogram to Predict the Response of First-Line Tyrosine Kinase Inhibitors or Chemotherapy in Non-small Cell Lung Cancer Patients With Epidermal Growth Factor Receptor-Mutant Status.Frontiers in medicine · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
20 authors at 2 institutions in 2 countries.
Qian Li1 Department of Hematology and Blood and Marrow Transplantation, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer. Tianjin's Clinical Research Center for Cancer. Key Laboratory of Cancer Prevention and Therapy, Tianjin, China.
Jing Ma1 Department of Hematology and Blood and Marrow Transplantation, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer. Tianjin's Clinical Research Center for Cancer. Key Laboratory of Cancer Prevention and Therapy, Tianjin, China.ORCID 0000-0002-0539-1544
Han Li1 Department of Hematology and Blood and Marrow Transplantation, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer. Tianjin's Clinical Research Center for Cancer. Key Laboratory of Cancer Prevention and Therapy, Tianjin, China.
Wengui Xu1 Department of Hematology and Blood and Marrow Transplantation, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer. Tianjin's Clinical Research Center for Cancer. Key Laboratory of Cancer Prevention and Therapy, Tianjin, China.
Zeng Cao1 Department of Hematology and Blood and Marrow Transplantation, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer. Tianjin's Clinical Research Center for Cancer. Key Laboratory of Cancer Prevention and Therapy, Tianjin, China.
Su Liu1 Department of Hematology and Blood and Marrow Transplantation, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer. Tianjin's Clinical Research Center for Cancer. Key Laboratory of Cancer Prevention and Therapy, Tianjin, China.
Lin Chen1 Department of Hematology and Blood and Marrow Transplantation, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer. Tianjin's Clinical Research Center for Cancer. Key Laboratory of Cancer Prevention and Therapy, Tianjin, China.
Shuang Gao1 Department of Hematology and Blood and Marrow Transplantation, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer. Tianjin's Clinical Research Center for Cancer. Key Laboratory of Cancer Prevention and Therapy, Tianjin, China.
Tinghui Yan1 Department of Hematology and Blood and Marrow Transplantation, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer. Tianjin's Clinical Research Center for Cancer. Key Laboratory of Cancer Prevention and Therapy, Tianjin, China.
Dongying Li1 Department of Hematology and Blood and Marrow Transplantation, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer. Tianjin's Clinical Research Center for Cancer. Key Laboratory of Cancer Prevention and Therapy, Tianjin, China.
Xue Wang1 Department of Hematology and Blood and Marrow Transplantation, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer. Tianjin's Clinical Research Center for Cancer. Key Laboratory of Cancer Prevention and Therapy, Tianjin, China.
Yuanfang Yue1 Department of Hematology and Blood and Marrow Transplantation, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer. Tianjin's Clinical Research Center for Cancer. Key Laboratory of Cancer Prevention and Therapy, Tianjin, China.
Zhigang Zhao1 Department of Hematology and Blood and Marrow Transplantation, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer. Tianjin's Clinical Research Center for Cancer. Key Laboratory of Cancer Prevention and Therapy, Tianjin, China.
Xiaofang Wang1 Department of Hematology and Blood and Marrow Transplantation, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer. Tianjin's Clinical Research Center for Cancer. Key Laboratory of Cancer Prevention and Therapy, Tianjin, China.
Hongliang Yang1 Department of Hematology and Blood and Marrow Transplantation, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer. Tianjin's Clinical Research Center for Cancer. Key Laboratory of Cancer Prevention and Therapy, Tianjin, China.
Haifeng Zhao1 Department of Hematology and Blood and Marrow Transplantation, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer. Tianjin's Clinical Research Center for Cancer. Key Laboratory of Cancer Prevention and Therapy, Tianjin, China.
Yong Yu1 Department of Hematology and Blood and Marrow Transplantation, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer. Tianjin's Clinical Research Center for Cancer. Key Laboratory of Cancer Prevention and Therapy, Tianjin, China.
Yizhuo Zhang1 Department of Hematology and Blood and Marrow Transplantation, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer. Tianjin's Clinical Research Center for Cancer. Key Laboratory of Cancer Prevention and Therapy, Tianjin, China.
Feiyue Fan3 Institute of Laboratory Animal Sciences, Chinese Academy of Medical Science and Peking Union Medical College, Beijing, China.
Yafei Wang1 Department of Hematology and Blood and Marrow Transplantation, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer. Tianjin's Clinical Research Center for Cancer. Key Laboratory of Cancer Prevention and Therapy, Tianjin, China.
Tianjin Medical University Cancer Institute and Hospital · CNChinese Academy of Medical Sciences & Peking Union Medical College · CN
Funding
No grant is acknowledged in the PubMed record.
Abstract
The aim of this study was to evaluate the relationship of prognosis of patients with multiple myeloma having extramedullary involvement (EMM) with the
Indexed as
Fluorodeoxyglucose F18Positron Emission Tomography Computed TomographyAgedAged, 80 and overAntineoplastic Combined Chemotherapy ProtocolsBiopsyFemaleHumansKi-67 AntigenMaleMiddle AgedMultiple MyelomaNeoplasm MetastasisNeoplasm StagingPrognosisSurvival AnalysisFluorodeoxyglucose F18Ki-67 Antigenextramedullary involvementKi-67multiple myelomaPET-CTsurvival analysis
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY-NC
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.